维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

8篇 您的检索式：作者名="Dent Andrew"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Hyperglycemia Affects Gastric Electrical Rhythm and Nausea During Intraduodenal Triglyceride Infusion显示文摘	Geoffrey S. Hebbard Melvin Samsom Jane M. Andrews David Carman Ben Tansell Wei Ming Sun John Dent Michael Horowitz	1997	Digestive Diseases and Sciences1997，，3：	1
	2	Characterisation of salt films on dissolving metal surfaces in artificial corrosion pits via in situ synchrotron X-ray diffraction显示文摘	Trevor Rayment Alison J. Davenport Andrew J. Dent Jean-Philippe Tinnes Richard J.K. Wiltshire Christopher Martin Graham Clark Paul Quinn J. Fred W. Mosselmans	2008	Electrochemistry Communications2008，，6：	1
	3	The effects of fuel chemistry and feedstock powder structure on the mechanical and tribological properties of HVOF thermal sprayed WC-Co coatings with very fine structures显示文摘	Qiao Yunfei Traugott E Fischer Andrew Dent	2003	Surface and Coatings Technology2003，172，1：	1
	4	The effects of fuel chemistry and feedstock powder structure on the mechanical and tribological properties of HVOF thermal-sprayed WC–Co coatings with very fine structures显示文摘	Yunfei Qiao Traugott E Fischer Andrew Dent	2003	Surface & Coatings Technology2003，，1：	1
	5	The effects of fuel chemistry and feedstock powder structure on the mechanical and tribological properties of HVOF thermal-sprayed WC-Co coatings with very fine structures 显示文摘	Qiao Yunfei Traugott E F Andrew Dent	2003	Surface and Coatings Technology2003，172，：	1
	6	Comparison of HVOF and plasma-sprayed alumina/titania coatings-microstructure,mechanical,properties and abrasion behavior显示文摘	Liu Yourong Fischer Traugott E Dent Andrew	2003	Surface and Coatings Technology2003，167，1：	1
	7	Comparison of HVOF and plasma-sprayed aluminay/titania coatings-microstructure,mechanical properties and abrasion behavior显示文摘	Liu Y R Traugott E Fischer Andrew Dent	2003	Surface and Coatings Technology2003，167，1：	1
	8	Kinase inhibitors:look beyond the label on the bottle显示文摘The majority of scientists working in the field of cancer experimental therapeutics recognize that many drugs that claim to be“specific”for one target enzyme in fact regulate to varying degrees the activities of other additional protein targets.Some of these targets are known and are recognized as being an essential component of a drug’s biology.However,many other targets fall into the category of“unknown unknowns”.Thus,the collective therapeutic outcome for almost all clinically relevant drugs is reliant on both the claimed primary and secondary“on”targets as well as some of the unexpected unknown“off”targets.This review discusses the biology of several FDA approved cancer therapeutic drugs whose initial reported targets only represented the tip-of-the-iceberg in terms of how each agent acted as an anti-tumor drug.The review also discusses a putative thorough pre-visualization methodology for drug-based research,prior to executing any wet work.These approaches should be performed in an agnostic fashion and be based in part on the clinically safe drug’s C max and its area under the curve in a patient.Based on tumor heterogeneity,considerations of how to approach developmental therapeutics in the age of“personalized medicine”are also discussed.	Paul Dent Andrew Poklepovic Laurence Booth John F.Hancock	2019	Cancer Drug Resistance2019，2，4：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费